SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters ...

PRINCETON, NJ - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotech company with a market capitalization of $4.63 million, has expanded its Phase 1 SB101 clinical trial to ...